Baxter International (BAX)
(Delayed Data from NYSE)
$38.71 USD
+0.37 (0.97%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $38.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.71 USD
+0.37 (0.97%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $38.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth F Momentum C VGM
Zacks News
Perrigo (PRGO) Q2 Earnings Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 10.42% and 5.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Baxter (BAX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Baxter (BAX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Baxter's (BAX) Helion Surgical System Debuts in Thailand
by Zacks Equity Research
Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?
by Zacks Equity Research
Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.
Should Value Investors Buy Baxter International (BAX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit
by Zacks Equity Research
Carlyle Group (CG) is in talks to acquire Baxter's kidney care unit. The companies started exclusive negotiations in late June and an agreement could be announced as soon as this week.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Company News for July 8, 2024
by Zacks Equity Research
Companies In The News Article are: M, LI, BAX, CG and AMD.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Baxter International (BAX) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
by Zacks Equity Research
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Compared to Estimates, Baxter (BAX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
Baxter International (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 6.56% and 1.20%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
Ahead of Baxter (BAX) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
by Zacks Equity Research
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.